ADPT Key Statistics, Chart & Performance
The current stock price of ADPT is 18.165 USD. In the past month the price increased by 3.35%. In the past year, price increased by 119.9%.
ADPT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to ADPT. When comparing the yearly performance of all stocks, ADPT is one of the better performing stocks in the market, outperforming 94.25% of all stocks.
ADPT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ADPT. ADPT has a bad profitability rating. Also its financial health evaluation is rather negative.
ADPT Financial Highlights
Over the last trailing twelve months ADPT reported a non-GAAP Earnings per Share(EPS) of -0.54. The EPS increased by 53.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.29% | ||
| ROE | -39.09% | ||
| Debt/Equity | 0.63 |
ADPT Forecast & Estimates
14 analysts have analysed ADPT and the average price target is 20.4 USD. This implies a price increase of 12.3% is expected in the next year compared to the current price of 18.165.
For the next year, analysts expect an EPS growth of 54.26% and a revenue growth 48.97% for ADPT
ADPT Ownership
About ADPT
Company Profile
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 619 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Company Info
ADAPTIVE BIOTECHNOLOGIES
1165 Eastlake Ave E
Seattle WASHINGTON 98102 US
CEO: Chad Robins
Employees: 619
Phone: 12066590067
ADAPTIVE BIOTECHNOLOGIES / ADPT FAQ
Can you describe the business of ADAPTIVE BIOTECHNOLOGIES?
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 619 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
What is the current price of ADPT stock?
The current stock price of ADPT is 18.165 USD. The price increased by 3.39% in the last trading session.
What is the dividend status of ADAPTIVE BIOTECHNOLOGIES?
ADPT does not pay a dividend.
How is the ChartMill rating for ADAPTIVE BIOTECHNOLOGIES?
ADPT has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of ADAPTIVE BIOTECHNOLOGIES (ADPT)?
ADAPTIVE BIOTECHNOLOGIES (ADPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.54).
Is ADAPTIVE BIOTECHNOLOGIES (ADPT) expected to grow?
The Revenue of ADAPTIVE BIOTECHNOLOGIES (ADPT) is expected to grow by 48.97% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the next earnings date for ADPT stock?
ADAPTIVE BIOTECHNOLOGIES (ADPT) will report earnings on 2026-02-17, after the market close.